Advances in Nonresponsive and Refractory Celiac Disease.

Area of Science:

• Gastroenterology
• Immunology
• Oncology

Background:

• Nonresponsive celiac disease (CeD) is common and usually linked to dietary non-adherence.
• Excluding other CeD complications and mimicking disorders is crucial for diagnosis.
• Refractory celiac disease (RCeD) is rare and presents diagnostic challenges.

Purpose of the Study:

• To differentiate between nonresponsive CeD, type I RCeD, and type II RCeD.
• To highlight the diagnostic criteria and therapeutic approaches for RCeD subtypes.
• To underscore the need for novel therapies for RCeD, particularly type II.

Main Methods:

• Diagnosis of CeD and RCeD subtypes based on clinical presentation, dietary adherence, and endoscopic/histological findings.
• Exclusion of other conditions mimicking CeD.
• Immunophenotypic analysis to identify clonal neoplastic intraepithelial lymphocytes in type II RCeD.

Main Results:

• Type I RCeD is a diagnosis of exclusion, necessitating the ruling out of gluten intake and non-malignant villous atrophy.
• Type II RCeD is characterized by a clonal population of neoplastic intraepithelial lymphocytes.
• Both RCeD types may respond to budesonide, but type II has a poor prognosis due to malnutrition and lymphoma risk.

Conclusions:

• Accurate diagnosis of RCeD subtypes is essential for appropriate management.
• Current therapies offer limited benefit for type II RCeD, emphasizing the need for advanced treatment strategies.
• Further research into novel therapies is critical to improve outcomes for patients with refractory celiac disease.